COBRE: RIH: THEME A: FETAL PROTEINS & PHENOTYPES IN CANCER: NOVEL HCC VACCINES

COBRE：RIH：主题 A：胎儿蛋白质

• 批准号: 7381873
• 负责人: MAUREEN A CHUNG
• 金额: $ 2.43万
• 依托单位: RHODE ISLAND HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7381873
• 关键词: COBRE; RIH; THEME; FETAL; PROTEINS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The object of this COBRE project is to design BCG vaccines that target TuAg1 (CD155) and MUC1. Theme A: Significance of Fetal Protein and Phenotypes in Cancer Novel Hepatocellular Vaccines Targeting Rat CD155 and MUC1 This research is focused on the development of novel vaccines for the prevention and/or treatment of cancer. The objective of this project is to develop innovative cancer vaccines that may be useful in the management of patients at risk for, or with ,hepatocellular carcinoma. Hepatocellular carcinoma is a leading cause of cancer mortality worldwide and frequently develops in patients with liver cirrhosis secondary to alcohol abuse or viral infections. Her vaccine uses BCG that have been genetically altered to express interleukin-2 and TuAg1, a tumor associated antigen over-expressed in hepatocellular carcinoma

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。该COBRE项目的目标是设计靶向TuAg 1（CD 155）和MUC 1的BCG疫苗。主题A：胎儿蛋白和表型在癌症中的意义针对大鼠CD 155和MUC 1的新型肝细胞疫苗该研究的重点是开发用于预防和/或治疗癌症的新型疫苗。该项目的目标是开发创新的癌症疫苗，可能有助于管理有肝细胞癌风险或患有肝细胞癌的患者。 肝细胞癌是世界范围内癌症死亡的主要原因，经常发生在继发于酒精滥用或病毒感染的肝硬化患者中。她的疫苗使用的BCG经过基因改造，可以表达白细胞介素-2和TuAg 1（一种在肝细胞癌中过度表达的肿瘤相关抗原）。